Rakuten Medical has appointed Minami Maeda as its new full-time CEO, tasking him with accelerating the global rollout of the company’s Alluminox® photoimmunotherapy platform. The leadership transition, which elevates current CEO Mickey Mikitani to Executive Chairman, is designed to streamline decision-making as the firm prepares for upcoming U.S. regulatory filings and commercial expansion, according to a company announcement.
How will the leadership change impact clinical trials?
The appointment of Maeda as a dedicated, full-time CEO aims to sharpen organizational execution during the critical Phase 3 clinical trial phase. Rakuten Medical is currently running a global study (ASP-1929-381, NCT06699212) evaluating the combination of ASP-1929 and pembrolizumab as a first-line treatment for recurrent head and neck cancer. According to the company, patient enrollment for this trial is currently ahead of schedule across sites in the United States, Japan, Taiwan, and Ukraine.
What is the status of the Alluminox platform?
The Alluminox platform combines drug administration with targeted light illumination to induce selective cell necrosis. While the treatment is approved for use in Japan under the brand name Akalux™ for unresectable head and neck cancer, it remains an investigational technology elsewhere. Rakuten Medical reports that it is leveraging clinical data and real-world evidence from the Japanese market to support its goal of submitting a Biologics License Application (BLA) to the U.S. FDA in 2028.
Compared to traditional systemic chemotherapy, which often impacts healthy tissue, the Alluminox approach utilizes a light-activatable dye (IRDye® 700DX) that binds specifically to tumor cells. This targeted mechanism is currently being tested across diverse tumor types beyond the head and neck, supported by external research grants.
Why is Rakuten shifting its corporate structure now?
The transition separates the roles of long-term strategic vision and daily operational management. By moving to Executive Chairman, Mikitani will focus on high-level growth initiatives and the company’s mission of “Conquering Cancer,” a goal he has pursued for 13 years. Maeda, who joined the company in 2017, is tasked with the “agile decision-making” required to navigate the complexities of international regulatory approval processes.
Frequently Asked Questions
- Is ASP-1929 available in the U.S. today? No. Outside of Japan, ASP-1929 is considered an investigational therapy and is not approved for commercial use by the FDA or other international regulatory bodies.
- What is the primary goal of the current Phase 3 trial? The trial (NCT06699212) aims to evaluate whether the combination of ASP-1929 and pembrolizumab provides an effective first-line treatment for patients with recurrent head and neck cancer.
- How does the treatment work? The process involves two steps: injecting a cell-targeting drug that binds to tumor cells, followed by local illumination with a 690nm red light laser to trigger selective cell death.
Are you following the latest developments in cancer immunotherapy? Subscribe to our newsletter for updates on global clinical trial milestones and biotech leadership shifts.